NCT02510417View on ClinicalTrials.gov

Allogeneic Virus-specific T Cell Lines (VSTs)

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 28, 2014

Primary Completion Date

September 11, 2017

Study Completion Date

January 3, 2018

Conditions
Viral Infections After HSCT
Interventions
BIOLOGICAL

VSTs

most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus

Trial Locations (1)

20010

Childrens National Medical Center, Washington D.C.

All Listed Sponsors
lead

Catherine Bollard

OTHER

NCT02510417 - Allogeneic Virus-specific T Cell Lines (VSTs) | Biotech Hunter | Biotech Hunter